Scinai Immunotherapeutics (SCNI) Competitors $3.31 -0.03 (-0.90%) Closing price 02/18/2025 03:59 PM EasternExtended Trading$3.31 0.00 (-0.03%) As of 02/18/2025 06:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestTrends SCNI vs. DWTX, TXMD, BCDA, PMCB, KPRX, TLPH, BCTX, PHXM, AEON, and CYCNShould you be buying Scinai Immunotherapeutics stock or one of its competitors? The main competitors of Scinai Immunotherapeutics include Dogwood Therapeutics (DWTX), TherapeuticsMD (TXMD), BioCardia (BCDA), PharmaCyte Biotech (PMCB), Kiora Pharmaceuticals (KPRX), Talphera (TLPH), BriaCell Therapeutics (BCTX), PHAXIAM Therapeutics (PHXM), AEON Biopharma (AEON), and Cyclerion Therapeutics (CYCN). These companies are all part of the "pharmaceutical products" industry. Scinai Immunotherapeutics vs. Dogwood Therapeutics TherapeuticsMD BioCardia PharmaCyte Biotech Kiora Pharmaceuticals Talphera BriaCell Therapeutics PHAXIAM Therapeutics AEON Biopharma Cyclerion Therapeutics Dogwood Therapeutics (NASDAQ:DWTX) and Scinai Immunotherapeutics (NASDAQ:SCNI) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, profitability, analyst recommendations, community ranking, valuation, earnings and risk. Which has higher valuation & earnings, DWTX or SCNI? Dogwood Therapeutics is trading at a lower price-to-earnings ratio than Scinai Immunotherapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDogwood TherapeuticsN/AN/A-$5.30M-$6.55-0.91Scinai ImmunotherapeuticsN/AN/A-$6.50M-$239.17-0.01 Which has more risk and volatility, DWTX or SCNI? Dogwood Therapeutics has a beta of 1.92, meaning that its share price is 92% more volatile than the S&P 500. Comparatively, Scinai Immunotherapeutics has a beta of 2.37, meaning that its share price is 137% more volatile than the S&P 500. Does the media prefer DWTX or SCNI? In the previous week, Scinai Immunotherapeutics had 1 more articles in the media than Dogwood Therapeutics. MarketBeat recorded 1 mentions for Scinai Immunotherapeutics and 0 mentions for Dogwood Therapeutics. Scinai Immunotherapeutics' average media sentiment score of 1.00 beat Dogwood Therapeutics' score of 0.00 indicating that Scinai Immunotherapeutics is being referred to more favorably in the news media. Company Overall Sentiment Dogwood Therapeutics Neutral Scinai Immunotherapeutics Positive Is DWTX or SCNI more profitable? Scinai Immunotherapeutics' return on equity of 0.00% beat Dogwood Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Dogwood TherapeuticsN/A -217.12% -172.06% Scinai Immunotherapeutics N/A N/A -30.48% Does the MarketBeat Community favor DWTX or SCNI? Dogwood Therapeutics and Scinai Immunotherapeutics both received 0 outperform votes by MarketBeat users. CompanyUnderperformOutperformDogwood TherapeuticsN/AN/AScinai ImmunotherapeuticsN/AN/A Do institutionals and insiders believe in DWTX or SCNI? 9.1% of Dogwood Therapeutics shares are held by institutional investors. Comparatively, 58.4% of Scinai Immunotherapeutics shares are held by institutional investors. 12.2% of Dogwood Therapeutics shares are held by insiders. Comparatively, 60.9% of Scinai Immunotherapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. SummaryScinai Immunotherapeutics beats Dogwood Therapeutics on 8 of the 10 factors compared between the two stocks. Get Scinai Immunotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SCNI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SCNI vs. The Competition Export to ExcelMetricScinai ImmunotherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.81M$3.10B$5.77B$9.20BDividend YieldN/A1.67%5.29%3.98%P/E Ratio-0.0147.2326.4419.51Price / SalesN/A333.31449.4569.98Price / CashN/A192.7646.0638.90Price / Book-0.344.057.255.07Net Income-$6.50M-$40.60M$3.19B$222.54M7 Day Performance-0.30%3.18%1.41%2.13%1 Month Performance-5.70%3.69%3.50%1.63%1 Year Performance-31.08%-12.15%20.82%16.41% Scinai Immunotherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SCNIScinai Immunotherapeutics1.4332 of 5 stars$3.31-0.9%N/A-31.1%$2.81MN/A-0.0120Positive NewsGap UpDWTXDogwood TherapeuticsN/A$8.77-18.3%N/AN/A$11.68MN/A-1.345Gap DownTXMDTherapeuticsMD1.1985 of 5 stars$1.01-1.0%N/A-54.9%$11.65M$1.60M0.00420Gap DownBCDABioCardia3.2085 of 5 stars$2.37flat$25.00+954.9%-59.5%$10.86M$480,000.00-0.5740Gap DownPMCBPharmaCyte Biotech0.7371 of 5 stars$1.55+4.0%N/A-23.7%$10.80MN/A2.924Negative NewsGap DownKPRXKiora Pharmaceuticals2.6663 of 5 stars$3.60flat$10.00+177.8%-35.2%$10.80MN/A0.0010Short Interest ↑TLPHTalphera2.6811 of 5 stars$0.63-3.1%$4.33+587.9%-50.1%$10.73M$650,000.00-0.9119BCTXBriaCell Therapeutics3.3617 of 5 stars$3.62-2.9%$32.00+784.0%-89.6%$10.68MN/A-0.278Positive NewsGap UpPHXMPHAXIAM TherapeuticsN/A$3.10flatN/AN/A$10.58M$32.66M0.0049AEONAEON Biopharma2.3199 of 5 stars$0.13-0.3%$5.00+3,749.1%-98.9%$10.39MN/A0.725Gap DownCYCNCyclerion Therapeutics0.9726 of 5 stars$3.82-9.3%N/A+7.3%$10.35M$1.62M0.0030Negative News Related Companies and Tools Related Companies Dogwood Therapeutics Alternatives TherapeuticsMD Alternatives BioCardia Alternatives PharmaCyte Biotech Alternatives Kiora Pharmaceuticals Alternatives Talphera Alternatives BriaCell Therapeutics Alternatives PHAXIAM Therapeutics Alternatives AEON Biopharma Alternatives Cyclerion Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SCNI) was last updated on 2/19/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | SponsoredAmerica cannot power AIThere’s a fatal flaw at the heart of the AI revolution… With AI continuing to explode in popularity, tech c...Porter & Company | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Scinai Immunotherapeutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Scinai Immunotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.